April 12, 2019
Shionogi said on April 11 that its US subsidiary Shionogi Inc. has entered into a license agreement with US-based BioDelivery Sciences International for the commercialization of its opioid-induced constipation (OIC) treatment Symproic (naldemedine) in the US. Under the deal, Shionogi...read more